Inhaled Levodopa as a Potential Treatment for Diphasic Dyskinesia

Mov Disord. 2021 Jan;36(1):265-266. doi: 10.1002/mds.28361. Epub 2020 Nov 5.

Authors

Gerard Saranza¹, Anthony E Lang^{1

2}

Affiliations

¹ Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, Ontario, Canada.
² Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

PMID: 33150990
DOI: 10.1002/mds.28361

No abstract available

Publication types

Letter

MeSH terms

Antiparkinson Agents / adverse effects
Dyskinesia, Drug-Induced* / drug therapy
Dyskinesia, Drug-Induced* / etiology
Humans
Levodopa / adverse effects
Parkinson Disease* / drug therapy

Substances

Antiparkinson Agents
Levodopa